Ovagen

1. Overview

Ovagen is a synthetic tripeptide with the amino acid sequence Glu-Asp-Leu (EDL) and a molecular weight of 375.37 g/mol (C15H25N3O8). Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it belongs to the class of ultrashort peptide bioregulators designed to restore organ-specific function through epigenetic modulation of gene expression [6][7]. Ovagen was derived from liver tissue extracts and is positioned within the Khavinson framework as a bioregulator primarily targeting liver and gastrointestinal tract function [5].

The peptide is structurally related to Bronchogen (AEDL), a tetrapeptide lung bioregulator that shares the EDL sequence at its C-terminus [2]. This relationship illustrates a recurring pattern in the Khavinson peptide family, where overlapping sequences produce tissue-specific effects depending on peptide length and amino acid composition [2][3].

Ovagen's primary researched effect is the modulation of cellular aging markers. In cell culture studies, it has been shown to increase expression of the proliferation marker Ki-67 while decreasing expression of apoptosis and senescence markers including p53, p16, and p21, and increasing expression of the longevity-associated sirtuin SIRT-6 [1]. These effects were observed in both young and aged cell cultures, with particularly dramatic changes reported in aged liver tissue [1].

As with most Khavinson bioregulator peptides, Ovagen's research base is limited primarily to publications from Khavinson's group and affiliated institutions. No human clinical trials have been registered or published, and independent replication of its biological effects by outside laboratories is absent.

Sequence

Glu-Asp-Leu (EDL)

Molecular Formula

C15H25N3O8

Molecular Weight

375.37 g/mol

Type

Synthetic tripeptide (Khavinson liver/GI bioregulator)

Source

Synthetic analog of peptide isolated from liver tissue extracts

Mechanism

Epigenetic regulation of gene expression; modulation of proliferation (Ki-67) and apoptosis (p53) markers; senescence marker regulation (p16, p21, SIRT-6)

Cellular Transport

POT family transporters (PepT1, PepT2)

Routes Studied

In vitro (cell cultures); oral capsules (animal/supplement)

FDA Status

Not approved; no clinical trials registered

Related Peptides

Livagen (KEDA), Bronchogen (AEDL), Epithalon (AEDG)

2. Mechanism of Action

Ovagen is proposed to act through epigenetic regulation of gene expression, with its biological effects attributed to direct interactions between the peptide and nuclear components including DNA and histone proteins.

Peptide-DNA Interaction

According to the Khavinson bioregulator theory, ultrashort peptides (2-7 amino acids) can penetrate cell membranes and nuclear membranes to interact directly with double-stranded DNA and histone proteins [3][8]. In molecular modeling studies, the EDL tripeptide forms energetically favorable complexes with d(ATATATATAT)2 sequences in the minor groove of DNA [1]. This interaction is proposed to alter chromatin conformation, making specific gene regions more accessible for transcription [3][11].

The broader evidence supporting this mechanism comes from fluorescence-labeling studies demonstrating that short peptides can penetrate into the nucleus of HeLa cells and interact specifically with DNA sequences in vitro [8]. These interactions are proposed to modulate transcription by altering the physical accessibility of gene promoter regions [3][9].

Cellular Transport via POT Transporters

Ovagen, as a tripeptide, falls within the substrate range of proton-coupled oligopeptide transporters of the POT family, specifically PepT1 (SLC15A1) and PepT2 (SLC15A2) [2]. These transporters are expressed in intestinal epithelium, kidney, liver, and other tissues, providing a mechanism for tissue-specific uptake of the peptide following oral administration. The tissue distribution of these transporters may partially explain the liver and gastrointestinal selectivity attributed to Ovagen [2].

Modulation of Aging Markers

The most specific mechanistic data for Ovagen comes from renal cell culture studies [1]. EDL treatment produced the following molecular effects:

• Increased proliferation: Upregulation of Ki-67, a marker of active cell division. In aged liver tissue specifically, Ovagen has been reported to produce an 18-fold increase in Ki-67 expression [1][5].
• Decreased apoptosis: Downregulation of p53, a tumor suppressor protein that promotes apoptosis and cell cycle arrest. A 6-fold decrease in p53 expression was reported in aged liver tissue [1].
• Reduced senescence: Decreased expression of p16 and p21, cyclin-dependent kinase inhibitors associated with cellular senescence and the irreversible arrest of cell division [1].
• Enhanced sirtuin activity: Increased expression of SIRT-6, a NAD-dependent deacetylase involved in DNA repair, telomere maintenance, and metabolic regulation. Reduced SIRT-6 synthesis was identified as a contributing cause of cell senescence in the renal cell model [1].

Chromatin Remodeling

Consistent with the broader Khavinson bioregulator framework, Ovagen is proposed to reverse age-related chromatin condensation in hepatocytes and gastrointestinal cells [5][11]. As cells age, progressive heterochromatinization silences previously active genes, reducing the cell's functional capacity. By restoring a more open chromatin state, Ovagen may re-enable transcription of genes necessary for normal tissue function and repair [3][11].

3. Researched Applications

Anti-Aging in Renal Cell Cultures

Evidence level: In vitro

The most quantitative data on Ovagen's biological effects comes from studies in young and aged renal cell cultures [1]. EDL and the related tripeptide AED both increased cell proliferation and modulated senescence markers, with EDL showing effects on p16, p21, p53 (decreased), and SIRT-6 (increased) [1]. Molecular modeling confirmed energetically favorable binding of EDL to specific DNA sequences, providing a potential structural basis for these gene expression changes [1].

Hepatoprotection

Evidence level: Preclinical (animal studies, reviews)

Ovagen's hepatoprotective properties are supported primarily by its inclusion in broader reviews of liver-derived peptide bioregulators [5]. The 2020 review by Kuznik, Khavinson, and Linkova evaluated the liver polypeptide complex (from which EDL-containing preparations are derived) and found concordant effects normalizing immune and antioxidant status and restoring liver function during experimentally induced hepatitis [5]. The maximal hepatoprotective effects were observed in aging animals, consistent with the bioregulator paradigm [5].

EDL is classified alongside Livagen (KEDA) as a liver-targeted peptide within the Khavinson system, though the two have distinct amino acid sequences and potentially complementary mechanisms of action [2][5].

Gastrointestinal Mucosal Protection

Evidence level: Preclinical (limited data)

Ovagen has been described as protective of gastrointestinal mucosal integrity, with proposed benefits in reducing damage from antibiotics, environmental toxins, chemotherapy, and malnutrition [5][13]. However, the specific experimental data supporting these GI claims are less well documented in the peer-reviewed literature than the hepatoprotective effects. The presence of PepT1 transporters in intestinal epithelium provides a mechanistic rationale for GI-targeted activity following oral administration [2].

Cell Differentiation Regulation

Evidence level: In vitro

In the 2020 review of peptide regulation of cell differentiation, EDL was identified as being involved in regulation of renal cell function, hepatoprotection, and DNA binding [2]. The related tetrapeptide AEDL (Bronchogen) was shown to induce lung cell differentiation by regulating expression of NKX2-1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2 genes [2]. These findings suggest that EDL-containing sequences have tissue-selective effects on cell differentiation pathways.

4. Clinical Evidence Summary

No human clinical trials have been conducted with Ovagen. All evidence derives from in vitro cell culture studies, animal models, and theoretical reviews. The clinical evidence gap is significant and represents the primary limitation in evaluating Ovagen's therapeutic potential.

5. Dosing in Research

No standardized human dosing has been established for Ovagen. Commercially available formulations typically contain 200 ug per capsule, with suggested protocols of 1-2 capsules daily for 10-20 days, repeated every 3-6 months. These protocols are not derived from dose-finding studies and have not been validated in controlled clinical research.

6. Relationship to Other Liver Peptides

Ovagen exists within a family of liver-targeted peptide bioregulators in the Khavinson system:

Livagen (KEDA, Lys-Glu-Asp-Ala) is a tetrapeptide derived from liver tissue extracts that primarily demonstrates chromatin decondensation effects in aged lymphocytes and inhibition of enkephalin-degrading enzymes. Livagen and Ovagen share the hepatoprotective classification but differ in their primary characterized mechanisms [5].

Bronchogen (AEDL, Ala-Glu-Asp-Leu) is a tetrapeptide lung bioregulator that shares the EDL sequence at its C-terminus. While Bronchogen targets lung cell differentiation, the overlapping EDL sequence suggests shared DNA-binding properties with potential tissue-specific differences determined by the additional N-terminal alanine residue [2].

Ventvil is the crude polypeptide extract from liver tissue that served as the source material from which both Livagen and Ovagen-related peptide fractions were identified. It contains a complex mixture of short peptides and has been tested in animal models of hepatitis and fibrosis [5].

7. Safety and Side Effects

No formal safety or toxicology studies have been published for Ovagen. The available safety-relevant observations are limited:

• In renal cell culture studies, EDL promoted proliferation and reduced apoptosis markers without reported cytotoxic effects [1]
• The parent liver polypeptide complex has been used in Russian clinical settings without reported adverse events, though systematic safety monitoring data are not available [5]
• As a naturally occurring tripeptide sequence, EDL is expected to be rapidly degraded by peptidases in plasma and tissues, limiting systemic exposure duration

Theoretical Concerns

• The simultaneous increase in Ki-67 (proliferation) and decrease in p53 (tumor suppressor) raises theoretical oncologic concerns, as this marker profile is characteristic of tumor cells rather than healthy tissue. No carcinogenicity studies have been conducted to address this concern.
• Long-term effects of repeated administration on liver cell proliferation kinetics are unknown.
• Drug interaction studies have not been performed.
• No pharmacokinetic data defining oral bioavailability, half-life, or metabolism are available.

8. Regulatory Status

Ovagen is not approved by the FDA, EMA, or any major Western regulatory agency. No clinical trials are registered on ClinicalTrials.gov. It is commercially available as a research peptide and as a dietary supplement component in some jurisdictions, but it is not a licensed pharmaceutical product. In Russia, the liver polypeptide complex from which Ovagen was conceptually derived has been used in clinical practice, but the synthetic EDL tripeptide does not hold separate pharmaceutical registration.

9. Limitations and Transparency

The evidence base for Ovagen has several critical limitations:

• All published research originates from the St. Petersburg Institute of Bioregulation and Gerontology and affiliated institutions
• No independent replication by laboratories outside the Khavinson research network
• The most dramatic effects reported (18-fold Ki-67 increase, 6-fold p53 decrease in aged liver tissue) have not been confirmed by independent groups
• Direct peer-reviewed publications specifically on the EDL tripeptide are limited; much of the evidence is drawn from broader reviews of Khavinson peptide bioregulators
• The proposed mechanism of direct peptide-DNA binding as a transcriptional regulatory mechanism remains outside mainstream molecular biology
• No clinical data of any kind exist for Ovagen

10. Pharmacokinetics

No pharmacokinetic studies have been published for Ovagen (EDL). As a tripeptide of 375 g/mol, it faces the standard ultrashort peptide pharmacokinetic challenges: rapid proteolytic degradation and uncertain oral bioavailability.

The identification of POT family transporters (PepT1, PepT2) as potential carriers for tripeptide-sized molecules provides a mechanistic basis for intestinal absorption of intact EDL [2]. PepT1 (SLC15A1) is expressed at high levels in intestinal epithelium and accepts tri- and dipeptides as substrates. PepT2 (SLC15A2) is expressed in kidney, liver, and other tissues, potentially providing a tissue-targeting mechanism after systemic absorption. The presence of PepT1 in liver tissue is consistent with Ovagen's proposed hepatic targeting.

However, no direct measurements of intact EDL transport via PepT1 have been published. The competition from dietary di- and tripeptides for PepT1 binding sites would be expected to limit absorption of microgram quantities of any single tripeptide. Furthermore, the leucine residue at the C-terminus is readily cleaved by carboxypeptidases in the intestinal lumen, potentially degrading EDL before it reaches PepT1.

The molecular modeling showing EDL binding to d(ATATATATAT)2 DNA sequences in the minor groove [1] was performed computationally and does not address whether sufficient intact peptide reaches cell nuclei in vivo to produce gene expression effects.

11. Dose-Response

No dose-response studies have been published for Ovagen. The renal cell culture study observed effects at experimental concentrations without systematic dose titration [1]. The dramatic effects reported in aged liver tissue (18-fold Ki-67 increase, 6-fold p53 decrease) [1][5] were observed at specific experimental conditions and have not been replicated across a dose range.

The commercial protocol (200 ug per capsule, 1-2 capsules daily for 10-20 days) follows the standard Khavinson bioregulator convention without Ovagen-specific dose optimization. No studies have compared different oral doses for any hepatic or renal endpoint.

The wide dose-activity relationship reported in Khavinson peptide studies (effects at concentrations spanning 10 to the minus 7 to 10 to the minus 12 M) raises questions about the precision of dose-response characterization, as most conventional pharmacological agents show much narrower dose-activity windows.

12. Comparative Effectiveness

Ovagen (EDL) vs. Livagen (KEDA)

Both are liver-targeted peptides in the Khavinson system, but with distinct characterized mechanisms. Livagen demonstrates chromatin decondensation in aged lymphocytes and enkephalinase inhibition (IC50 approximately 20 uM). Ovagen shows Ki-67 upregulation and p53/p16/p21 suppression in cell cultures. Livagen has more published peer-reviewed studies (chromatin studies in multiple independent publications from Georgian and Russian collaborators), while Ovagen's key data are drawn primarily from broader reviews. They are proposed to be complementary.

Ovagen (EDL) vs. Bronchogen (AEDL)

Bronchogen contains the EDL sequence at its C-terminus, with an additional N-terminal alanine residue. Despite this structural overlap, the two are classified as targeting different tissues (liver/GI vs. bronchial epithelium). Whether the shared EDL sequence confers shared biological activities (which would undermine tissue-specificity claims) or whether the additional alanine genuinely redirects tissue targeting is an unresolved question.

Ovagen vs. Conventional Hepatoprotective Agents

Established hepatoprotective agents (silymarin, UDCA, NAC, SAMe) have defined mechanisms, clinical trial evidence, and established safety profiles. Ovagen has zero human clinical data and operates through a proposed mechanism (direct peptide-DNA binding) that remains outside mainstream molecular biology. The evidence gap is fundamental.

13. Enhanced Safety

No adverse effects have been reported in Ovagen studies [1][5]. As a naturally occurring tripeptide sequence, EDL is expected to be rapidly degraded by endogenous peptidases, limiting systemic exposure duration and providing an inherent safety margin.

The simultaneous Ki-67 increase (proliferation) and p53 decrease (tumor suppressor) observed in cell cultures [1] represents the most significant theoretical safety concern. This marker profile (high Ki-67, low p53) is characteristic of malignant rather than healthy cells. While the Khavinson group interprets this as beneficial anti-senescence activity, conventional oncology would view sustained suppression of p53 with enhanced proliferation as potentially tumorigenic. No carcinogenicity or long-term safety studies have been conducted to address this concern.

The 18-fold Ki-67 increase reported in aged liver tissue is an exceptionally large effect that warrants particular scrutiny, as massive proliferative stimulation of hepatocytes could theoretically promote hepatocellular carcinoma development. This concern is amplified in patients with pre-existing liver disease (cirrhosis, chronic hepatitis), where hepatocyte turnover is already dysregulated.

No drug interaction studies, reproductive toxicity assessments, or pharmacokinetic safety evaluations have been published. The safety database consists entirely of negative observations (absence of reported harm) from in vitro experiments within Khavinson's research network.

14. Related Peptides

See also: Livagen, Epithalon, Pancragen, Pinealon

15. References

1. [1] Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Kvetnoy IM. (2014). Tripeptides slow down aging process in renal cell culture. Advances in Gerontology. PubMed
2. [2] Khavinson VKh, Linkova NS, Diatlova AS, Trofimova SV. (2020). Peptide regulation of cell differentiation. Stem Cell Reviews and Reports. DOI PubMed
3. [3] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
4. [4] Khavinson VKh, Linkova NS, Kvetnoy IM. (2015). Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Bulletin of Experimental Biology and Medicine. PubMed
5. [5] Kuznik BI, Khavinson VKh, Linkova NS. (2020). The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Advances in Gerontology. PubMed
6. [6] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
7. [7] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
8. [8] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
9. [9] Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
10. [10] Khavinson VKh, Malinin VV. (2005). Gerontological aspects of genome peptide regulation. Karger Publishers.
11. [11] Khavinson VKh, Lezhava TA. (2023). Epigenetic modification under the influence of peptide bioregulators on old chromatin. Advances in Gerontology. PubMed
12. [12] Kuznik BI, Linkova NS, Khavinson VKh. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences. DOI PubMed
13. [13] Khavinson VKh. (2020). Peptide medicines: past, present, future. Klinicheskaia Meditsina (Mosk).
14. [14] Morozov VG, Khavinson VKh. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology. DOI PubMed
15. [15] Khavinson VKh, Linkova NS, Kvetnoy IM. (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed